In critically ill adult ICU patients without acetaminophen overdose, what is the role of intravenous glutathione or intravenous N‑acetylcysteine as antioxidant therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Role of IV NAC as Antioxidant in Critical Care (Non-Acetaminophen Overdose)

Intravenous N-acetylcysteine (NAC) shows potential benefit as antioxidant therapy in critically ill ICU patients without acetaminophen overdose, with the strongest evidence supporting its use in ARDS and septic shock, though it should be considered adjunctive rather than standard therapy.

FDA-Approved Indication vs. Off-Label Use

The FDA-approved indication for IV NAC is exclusively for acetaminophen overdose 1. There are no FDA-approved indications for IV NAC as a general antioxidant in critical care. However, the mechanism of action—maintaining or restoring glutathione levels and acting as an alternative substrate for detoxification of reactive metabolites—provides biological plausibility for broader antioxidant applications 1.

Evidence for Antioxidant Use in Critical Care

ARDS (Acute Respiratory Distress Syndrome)

  • Most recent evidence (2021): NAC at 150 mg/kg loading dose followed by 50 mg/kg/day for 3 days showed significant improvement in level of consciousness, respiratory index (PaO2/FiO2), and PEEP requirements by days 3-4 in mechanically ventilated ARDS patients 2

  • Supporting biochemical evidence (2007): NAC increased intracellular glutathione, extracellular total antioxidant power, and total thiol molecules, with improved patient outcomes 3

  • COVID-19 ARDS (2023): NAC-treated patients demonstrated higher PaO2/FiO2 ratios and decreased inflammatory markers (CRP, D-dimer, LDH) after 3 days, with stabilization of glutathione concentrations 4

Septic Shock

  • Combined GSH + NAC therapy (2000): The combination of IV glutathione (70 mg/kg/day) plus NAC (75 mg/kg/day) produced marked decreases in peroxidative stress markers and significantly improved clinical scores compared to glutathione alone or standard care 5

  • This represents the only direct evidence for IV glutathione in critical care, though the study is older (2000)

Polytrauma

  • Vitamin C + NAC combination (2018): Combined antioxidant therapy showed significantly lower sepsis incidence, mortality rates, and improved APACHE II scores starting from day 5 6

Practical Dosing Algorithm

For ARDS or severe sepsis/septic shock:

  1. Loading dose: 150 mg/kg IV on day 1
  2. Maintenance: 50 mg/kg/day IV for days 2-4
  3. Duration: Typically 3-4 days based on clinical response

For combined therapy (septic shock):

  • Add IV glutathione 70 mg/kg/day to the NAC regimen above 5

Critical preparation requirements 1:

  • NAC is hyperosmolar (2600 mOsmol/L) and must be diluted in sterile water, 0.45% saline, or D5W
  • Adjust osmolarity to ≥150 mOsmol/L in pediatric patients
  • Diluted solution stable for 24 hours at room temperature

Important Caveats and Pitfalls

Monitoring Requirements

  • Watch for anaphylactoid reactions (hypotension, urticaria, bronchospasm)—these are dose-related and more common with rapid infusion
  • Monitor hepatic and renal function throughout treatment 1
  • Track clinical response markers: PaO2/FiO2, inflammatory markers, APACHE II scores

Limitations of Evidence

  • No large multicenter RCTs exist for non-acetaminophen indications
  • Studies are relatively small (n=27-140 patients)
  • Most evidence is from single-center trials
  • The 2000 septic shock study is dated but remains the only evidence for IV glutathione

When NOT to Use

  • Isolated organ dysfunction without oxidative stress component (e.g., simple volume overload, isolated renal failure)
  • Patients with known hypersensitivity to NAC
  • As monotherapy replacing standard critical care interventions

Clinical Decision Framework

Consider IV NAC when:

  1. Patient has ARDS requiring mechanical ventilation
  2. Septic shock with evidence of oxidative stress (elevated lactate, inflammatory markers)
  3. Polytrauma with systemic inflammatory response
  4. Within first 24 hours of ICU admission for maximum benefit

Expected timeline for response:

  • Biochemical markers improve by day 3
  • Clinical parameters (PaO2/FiO2, consciousness) improve by days 3-4
  • APACHE II scores decrease by day 5

The evidence supports NAC as a reasonable adjunctive therapy in ARDS and septic shock, but it does not replace standard critical care management including source control, appropriate antibiotics, hemodynamic support, and lung-protective ventilation.

References

Related Questions

In a 27-year-old woman who ingested 24 acetaminophen tablets (~12 g) after two prior suicide attempts, which of the following statements is incorrect: A) Risk of hepatic and renal injury; B) Immediate administration of N‑acetylcysteine; C) Measuring acetaminophen levels and delaying N‑acetylcysteine; D) Assessment of hepatic and renal function; E) Concomitant alcohol use increases toxicity?
Should N‑acetylcysteine (NAC) be administered concurrently with the maintenance IV fluids, or given as a separate IV infusion alone?
Should N‑acetylcysteine be administered to a 16‑year‑old female weighing 60 kg who has not ingested an acetaminophen overdose?
What is the role of intravenous glutathione thiol in the management of sepsis?
What oral and injectable strengths are available for prednisolone?
For a 77-year-old male with anxiety and depression who is taking lamotrigine (Lamictal) 200 mg daily, mirtazapine (Remeron) 15 mg at bedtime, and duloxetine 30 mg in the morning and 60 mg at bedtime, should a low‑dose atypical antipsychotic be added to augment his regimen, and what dose and monitoring are recommended?
For a 52‑year‑old patient with a BMI of 30.4, how can I obtain insurance approval for semaglutide (Wegovy) and which ICD‑10‑CM codes should be used?
For older adults with sarcopenia who are already taking leucine (≈3 g) and whey protein (20‑30 g) daily, how does the usefulness of β‑Hydroxy‑β‑methylbutyrate (HMB), Velocitol (amylopectin + chromium complex), and ursolic acid rank for building muscle mass?
What are the causes of recurrent shingles in a 64-year-old woman?
What is the appropriate evaluation and management for an 8-year-old girl with new-onset vocal tics who is being teased at school?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.